Our R&D center is located in Beijing, with more than 2000 square meters of scientific laboratories. The R&D team members come from internationally renowned pharmaceutical enterprises and universities, with doctoral degree and master's degree holders accounting for 31% and 75%, respectively.

MORE information

We have taken advantage of the liposome active targeted technology in improving drug safety and efficacy to conquer the difficulties with liposomes in particle size distribution, drug loading, entrapped efficiency, stability, etc., and have obtained 13 national patents for invention, 1 U.S. patent, and PCT patents covering the U.S., Europe, Japan, South Korea, Canada and Australia, forming a complete independent intellectual property system and successfully establishing an active targeted nanopharmaceuticals delivery technology platform.

MORE information

The pipeline covers AS moderate to severe, high-risk, and preventive indications, which can be expanded to tumors and autoimmunity

MORE information

In a groundbreaking achievement, Inno Medicine has developed an innovative targeted therapy of atherosclerosis, resulting from a successful technology transfer collaboration with Beijing Anzhen Hospital. This remarkable advancement enables precise and effective treatment of atherosclerosis by employing a unique active targeting delivery system, ensuring the drug reaches the intended site to deliver its therapeutic benefits. YN001 has received IND approval from the US FDA and China NMPA, becoming the world's first cardiovascular targeted drug to enter clinical trials, is expected to become the first cardiovascular drug in history to obtain FDA approval through Accelerated Approval, and become a disruptive treatment method in this field. 

MORE information